<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               1	INDICATIONS AND USAGE<BR>               <BR>               <BR>                  <BR>                     <BR>                        INCIVEK is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated, in combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C (CHC) in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have been previously treated with interferon-based treatment, including prior null responders, partial responders, and relapsers. (1) <BR>                        <BR>                            INCIVEK must not be used as monotherapy and must only be used in combination with peginterferon alfa and ribavirin. (5.6)<BR>                            A high proportion of previous null responders (particularly those with cirrhosis) did not achieve Sustained Virologic Response (SVR) and had telaprevir resistance-associated substitutions emerge on treatment with INCIVEK. (12.4, 14.3)<BR>                            INCIVEK efficacy has not been established for patients who have previously failed therapy with a treatment regimen that includes INCIVEK or other HCV NS3/4A protease inhibitors. (12.4)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.1	Chronic Hepatitis C<BR>                     <BR>                        INCIVEK™ (telaprevir), in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have previously been treated with interferon-based treatment, including prior null responders, partial responders, and relapsers [see<BR>                               Clinical Studies (14.2<BR>                            and <BR>                              14.3), including definitions of these terms].<BR>                        The following points should be considered when initiating treatment with INCIVEK:<BR>                        <BR>                            INCIVEK must not be administered as monotherapy and must only be prescribed with both peginterferon alfa and ribavirin [see <BR>                                 Warnings and Precautions (5.6)<BR>                              ].<BR>                            A high proportion of previous null responders (particularly those with cirrhosis) did not achieve a Sustained Virologic Response (SVR) and had telaprevir resistance-associated substitutions emerge on treatment with INCIVEK combination treatment [see<BR>                                  Microbiology (12.4)<BR>                               and<BR>                                  Clinical Studies (14.3)<BR>                              ].<BR>                            INCIVEK efficacy has not been established for patients who have previously failed therapy with a treatment regimen that includes INCIVEK or other HCV NS3/4A protease inhibitors [see <BR>                                 Microbiology (12.4)<BR>                              ].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>